Investigators have identified a novel protein called arginine methyltransferase 1 (PRMT1) that may serve as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC).
PDAC is the most common type of pancreatic cancer, with a 5-year survival rate of less than 10%. These poor outcomes further support the crucial need for identifying druggable targets essential for tumor maintenance. Read more . . .